Skip to content

Overview

Chinese Government provides COVID-19 vaccines to Niger in August 2022

Commitments (Constant USD, 2023)$6,803,418
Commitment Year2022Country of ActivityNigerDirect Recipient Country of IncorporationNigerSectorHealthFlow TypeGrant

Status

Project lifecycle

Completion

Pipeline: PledgePipeline: CommitmentImplementationCompletion

Timeline

Key dates

Commitment date
Aug 15, 2022
Start (actual)
Aug 15, 2022
End (actual)
Aug 15, 2022

Geospatial footprint

Map overview

Visualizes the AidData-provided feature geometry for this project.

Loading map…

The purpose of this project was to provide 400,000 COVID-19 vaccines to Niamey, Niger. More detailed locational information can be found at https://www.openstreetmap.org/relation/3218804.

Stakeholders

Organizations involved in projects and activities supported by financial and in-kind transfers from Chinese government and state-owned entities

Funding agencies

Government Agencies

  • Unspecified Chinese Government Institution

Receiving agencies

Government Agencies

  • Government of Niger

Loan desecription

Chinese Government provides COVID-19 vaccines to Niger in August 2022

Narrative

Full Description

Project narrative

On August 15, 2022, the Chinese Government provided 400,000 COVID-19 vaccines to Niger. The vaccines were delivered to Niamey, the capital of Niger. Jiang Feng, China's Ambassador to Niger, Tongni Minister of Culture, Tourism and Handicrafts, Hamid (Minister of Health of Deni), and Omaru, Executive Manager of the Nur Foundation founded by the wife of the President of Niger, attended the delivery ceremony at the airport. The estimated monetary value of this donation is $7,200,000 USD.

Staff comments

1. According to the UNICEF COVID-19 Vaccine Market Dashboard, the price of a single Sinovac COVID-19 vaccine dose is $18 (https://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DCD/DAC/STAT(2022)33&docLanguage=En). As such, AidData has estimated the monetary value of the August 2022 donation as $7.2 million.